New hope for rare cancer: drug combo trial targets NUT carcinoma

NCT ID NCT05019716

First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 33 times

Summary

This study tests a new drug, ZEN003694, combined with standard chemotherapy for people with a rare and aggressive cancer called NUT carcinoma. The goal is to find the safest dose and see if the combination can shrink tumors. About 36 adults with advanced or metastatic NUT carcinoma will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NUT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Phone: •••-•••-••••

  • Los Angeles General Medical Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • USC / Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

    Contact Phone: •••-•••-••••

  • University of Pittsburgh Cancer Institute (UPCI)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.